Merrill remains neutral on Onyx

Onyx Pharmaceuticals Inc. kept its neutral rating from Merrill Lynch analyst Eric Ende. The Food and Drug Administration approved Sutent for first-line advanced renal cell cancer GI stromal tumors, although Nexavar may have a near-term advantage due to survival data and safety. Phase 3 overall survival data for Sutent could be available later this year. Shares of the Emeryville, Calif., biopharmaceutical company were down 20 cents, or 0.72%, at $27.50 on volume of 1,393,920 shares versus the three-month running average of 1,096,420 shares. (Nasdaq: ONXX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.